Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

Erik S. Knudsen, Eileen M. O'Reilly, Jonathan R. Brody, Agnieszka K. Witkiewicz

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Patients with pancreatic ductal adenocarcinoma (PDA) have a poor prognosis despite new treatments; approximately 7% survive for 5 years. Although there have been advances in systemic, primarily cytotoxic, therapies, it has been a challenge to treat patients with PDA using targeted therapies. Sequence analyses have provided a wealth of information about the genetic features of PDA and have identified potential therapeutic targets. Preclinical and early-phase clinical studies have found specific pathways could be rationally targeted; it might also be possible to take advantage of the genetic diversity of PDAs to develop therapeutic agents. The genetic diversity and instability of PDA cells have long been thought of as obstacles to treatment, but are now considered exploitable features. We review the latest findings in pancreatic cancer genetics and the promise of targeted approaches in PDA therapy.

Original languageEnglish (US)
Pages (from-to)48-63
Number of pages16
JournalGastroenterology
Volume150
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Precision Medicine
Adenocarcinoma
Therapeutics
Pancreatic Neoplasms
Sequence Analysis

Keywords

  • Kras
  • Myc
  • Notch
  • Smad4

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. / Knudsen, Erik S.; O'Reilly, Eileen M.; Brody, Jonathan R.; Witkiewicz, Agnieszka K.

In: Gastroenterology, Vol. 150, No. 1, 01.01.2016, p. 48-63.

Research output: Contribution to journalArticle

Knudsen, Erik S. ; O'Reilly, Eileen M. ; Brody, Jonathan R. ; Witkiewicz, Agnieszka K. / Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. In: Gastroenterology. 2016 ; Vol. 150, No. 1. pp. 48-63.
@article{1d701214f20a4adc82ad8c1ea42c42c8,
title = "Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine",
abstract = "Patients with pancreatic ductal adenocarcinoma (PDA) have a poor prognosis despite new treatments; approximately 7{\%} survive for 5 years. Although there have been advances in systemic, primarily cytotoxic, therapies, it has been a challenge to treat patients with PDA using targeted therapies. Sequence analyses have provided a wealth of information about the genetic features of PDA and have identified potential therapeutic targets. Preclinical and early-phase clinical studies have found specific pathways could be rationally targeted; it might also be possible to take advantage of the genetic diversity of PDAs to develop therapeutic agents. The genetic diversity and instability of PDA cells have long been thought of as obstacles to treatment, but are now considered exploitable features. We review the latest findings in pancreatic cancer genetics and the promise of targeted approaches in PDA therapy.",
keywords = "Kras, Myc, Notch, Smad4",
author = "Knudsen, {Erik S.} and O'Reilly, {Eileen M.} and Brody, {Jonathan R.} and Witkiewicz, {Agnieszka K.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2015.08.056",
language = "English (US)",
volume = "150",
pages = "48--63",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

AU - Knudsen, Erik S.

AU - O'Reilly, Eileen M.

AU - Brody, Jonathan R.

AU - Witkiewicz, Agnieszka K.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Patients with pancreatic ductal adenocarcinoma (PDA) have a poor prognosis despite new treatments; approximately 7% survive for 5 years. Although there have been advances in systemic, primarily cytotoxic, therapies, it has been a challenge to treat patients with PDA using targeted therapies. Sequence analyses have provided a wealth of information about the genetic features of PDA and have identified potential therapeutic targets. Preclinical and early-phase clinical studies have found specific pathways could be rationally targeted; it might also be possible to take advantage of the genetic diversity of PDAs to develop therapeutic agents. The genetic diversity and instability of PDA cells have long been thought of as obstacles to treatment, but are now considered exploitable features. We review the latest findings in pancreatic cancer genetics and the promise of targeted approaches in PDA therapy.

AB - Patients with pancreatic ductal adenocarcinoma (PDA) have a poor prognosis despite new treatments; approximately 7% survive for 5 years. Although there have been advances in systemic, primarily cytotoxic, therapies, it has been a challenge to treat patients with PDA using targeted therapies. Sequence analyses have provided a wealth of information about the genetic features of PDA and have identified potential therapeutic targets. Preclinical and early-phase clinical studies have found specific pathways could be rationally targeted; it might also be possible to take advantage of the genetic diversity of PDAs to develop therapeutic agents. The genetic diversity and instability of PDA cells have long been thought of as obstacles to treatment, but are now considered exploitable features. We review the latest findings in pancreatic cancer genetics and the promise of targeted approaches in PDA therapy.

KW - Kras

KW - Myc

KW - Notch

KW - Smad4

UR - http://www.scopus.com/inward/record.url?scp=84952682738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952682738&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2015.08.056

DO - 10.1053/j.gastro.2015.08.056

M3 - Article

VL - 150

SP - 48

EP - 63

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -